Document Detail


Spontaneous reporting of adverse drug reactions to non-steroidal anti-inflammatory drugs. A report from the Spanish System of Pharmacovigilance, including an early analysis of topical and enteric-coated formulations.
MedLine Citation:
PMID:  7875178     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Non-steroidal anti-inflammatory drugs (NSAIDs) are the third most commonly prescribed group of drugs in Spain. We present here the profile of adverse drug reactions (ADRs) attributed to them and reported to the Spanish System of Pharmacovigilance (SSPV) between 1983 and 1991, together with a preliminary analysis of topical, slow-release (SR) and enteric-coated (EC) preparations. Out of 18,348 reports of ADRs included in the SSPV database, 1609 (8.8%) implicated an NSAID. NSAIDs ranked second after antibiotics (15.1% of all reports) among the most commonly implicated drugs. Half of the patients were more than 55 years old, and 60% were women. Diclofenac (364 reports), piroxicam (282), indomethacin (197), naproxen (155), and ketoprofen (137) were the most commonly implicated NSAIDs in reports of ADRs. The most commonly reported ADRs were gastrointestinal (39%), cutaneous (20%), and those affecting the central and peripheral nervous system (9%). Seven reactions had a fatal outcome, and 138 were considered life threatening. Forty-nine reports included previously undescribed ADRs. There were 98 reports describing ADRs attributed to topical NSAIDs; 5 of these described 11 general reactions, such as duodenal ulcer, gastrointestinal bleeding, diarrhoea, dyspnoea, facial oedema, aggravation of bronchospasm, and angioedema. One hundred and sixty-eight reports referred to SR and EC preparations. The ratio of gastrointestinal to non-gastrointestinal reactions to SR-EC diclofenac was higher in the case of SR-EC diclofenac than in the case of plain diclofenac (P = 0.037); similarly, the ratio of CNS to non-CNS reactions to SR-EC indomethacin was also higher than the corresponding ratio with plain indomethacin (P = 0.002).(ABSTRACT TRUNCATED AT 250 WORDS)
Authors:
A Figueras; D Capellà; J M Castel; J R Laorte
Related Documents :
15170768 - Comparison of data mining methodologies using japanese spontaneous reports.
15933288 - Crisis management during anaesthesia: problems associated with drug administration duri...
2966038 - Reported adverse reactions to and consumption of nonsteroidal anti-inflammatory drugs i...
20460818 - Prediction of severe adverse drug reactions using pharmacogenetic biomarkers.
13729628 - Analgesic-antipyretic drugs as inhibitors of kallikrein.
23668378 - 2012 annual meeting of the safety pharmacology society: spotlight on targeted oncology ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European journal of clinical pharmacology     Volume:  47     ISSN:  0031-6970     ISO Abbreviation:  Eur. J. Clin. Pharmacol.     Publication Date:  1994  
Date Detail:
Created Date:  1995-04-06     Completed Date:  1995-04-06     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  1256165     Medline TA:  Eur J Clin Pharmacol     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  297-303     Citation Subset:  IM    
Affiliation:
Departament de Farmacologia i psiquiatria, Universitat Autònoma de Barcelona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Cutaneous
Administration, Oral
Adverse Drug Reaction Reporting Systems*
Age Distribution
Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
Diclofenac / adverse effects*
Female
Formularies, Hospital
Humans
Indomethacin / adverse effects*
Male
Sex Distribution
Sex Factors
Spain
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 15307-86-5/Diclofenac; 53-86-1/Indomethacin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Nuclear medicine and other radiologic imaging techniques: competitors or collaborators?
Next Document:  Adverse reactions attributed to sumatriptan. A postmarketing study in general practice.